Fisher Asset Management LLC cut its stake in Enanta Pharmaceuticals Inc (NASDAQ:ENTA) by 16.8% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 12,214 shares of the biotechnology company’s stock after selling 2,469 shares during the period. Fisher Asset Management LLC owned approximately 0.06% of Enanta Pharmaceuticals worth $1,044,000 at the end of the most recent reporting period.
A number of other institutional investors also recently modified their holdings of ENTA. Acadian Asset Management LLC increased its holdings in Enanta Pharmaceuticals by 72.4% in the second quarter. Acadian Asset Management LLC now owns 381,729 shares of the biotechnology company’s stock valued at $44,242,000 after buying an additional 160,344 shares in the last quarter. First Manhattan Co. increased its holdings in Enanta Pharmaceuticals by 22.7% in the third quarter. First Manhattan Co. now owns 698,434 shares of the biotechnology company’s stock valued at $59,688,000 after buying an additional 129,026 shares in the last quarter. First Trust Advisors LP purchased a new position in Enanta Pharmaceuticals in the second quarter valued at about $8,029,000. BlackRock Inc. increased its holdings in Enanta Pharmaceuticals by 2.9% in the second quarter. BlackRock Inc. now owns 2,433,000 shares of the biotechnology company’s stock valued at $281,985,000 after buying an additional 68,564 shares in the last quarter. Finally, Federated Investors Inc. PA increased its holdings in Enanta Pharmaceuticals by 132,354.9% in the second quarter. Federated Investors Inc. PA now owns 67,552 shares of the biotechnology company’s stock valued at $7,829,000 after buying an additional 67,501 shares in the last quarter. 78.19% of the stock is owned by institutional investors.
Shares of ENTA opened at $79.88 on Friday. Enanta Pharmaceuticals Inc has a 1-year low of $44.52 and a 1-year high of $127.77. The company has a market cap of $1.50 billion, a PE ratio of 18.28 and a beta of 1.04.
Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Tuesday, August 7th. The biotechnology company reported $0.97 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.98 by ($0.01). Enanta Pharmaceuticals had a return on equity of 25.84% and a net margin of 37.63%. The business had revenue of $57.26 million for the quarter, compared to analysts’ expectations of $56.59 million. As a group, research analysts predict that Enanta Pharmaceuticals Inc will post 3.56 earnings per share for the current year.
In other news, insider Tim Ocain sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, October 1st. The shares were sold at an average price of $83.64, for a total transaction of $2,091,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Nathalie Adda sold 4,155 shares of the firm’s stock in a transaction that occurred on Thursday, September 20th. The stock was sold at an average price of $95.32, for a total transaction of $396,054.60. Following the transaction, the vice president now directly owns 4,155 shares of the company’s stock, valued at $396,054.60. The disclosure for this sale can be found here. Over the last three months, insiders have sold 33,310 shares of company stock valued at $2,870,644. Corporate insiders own 10.56% of the company’s stock.
A number of brokerages have issued reports on ENTA. Zacks Investment Research raised shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and set a $105.00 target price for the company in a report on Thursday, August 9th. BidaskClub raised shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday. Oppenheimer set a $100.00 target price on shares of Enanta Pharmaceuticals and gave the company a “hold” rating in a report on Tuesday, August 14th. UBS Group cut shares of Enanta Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 8th. Finally, JMP Securities reaffirmed a “buy” rating and issued a $120.00 target price on shares of Enanta Pharmaceuticals in a report on Tuesday, July 31st. Six investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $104.00.
Enanta Pharmaceuticals Profile
Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus.
Featured Story: Asset Allocation and Your Retirement
Want to see what other hedge funds are holding ENTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enanta Pharmaceuticals Inc (NASDAQ:ENTA).
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.